The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.
April 22nd 2024
The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.
The Evolution of Oncology Biosimilars and the Potential to Improve Patient Access to Biologics
March 2nd 2020A session on the use of biosimilars, a topic that many pharmacists identify to be of growing importance in their practices, concluded the 2019 Directions in Oncology Pharmacy conference.
Read More
Biosimilar Trastuzumab-dkst Launched in the US
December 2nd 2019Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.
Read More
FDA Approves Biosimilar for Multiple Inflammatory Conditions
November 18th 2019Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
Read More
Rheumatoid Arthritis Biosimilar Meets Equivalency Endpoints in Phase 1/3 Trial
January 25th 2019Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
Read More
How Can Pharmacists Approach Reimbursement Challenges to Improve Biosimilar Use?
December 4th 2018At the 2018 ASHP Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, offered advice on how pharmacy providers can work to overcome biosimilar reimbursement challenges and encourage biosimilar adoption.
Read More